

**PRECLINICAL *IN VITRO* STUDY ON AMIDINE-HYDROXAMIC ACID
BASED ANTIMALARIAL DRUG CANDIDATE.**

BY

**OPENIBO, JOHN OLUWAYOMI
B. Sc. Microbiology, Lagos State University, Lagos.
Matriculation number: 14PCQ01212**

**A DISSERTATION SUBMITTED TO THE DEPARTMENT OF
BIOLOGICAL SCIENCES (MICROBIOLOGY UNIT), COLLEGE OF
SCIENCE AND TECHNOLOGY, COVENANT UNIVERSITY, OTA,
NIGERIA
IN PARTIAL FULFILMENT OF THE REQUIREMENTS FOR THE
AWARD OF MASTER OF SCIENCE (MSc.) DEGREE IN
MICROBIOLOGY**

JUNE, 2017.

Acceptance

This is to attest that this dissertation is accepted in partial fulfilment of the requirements for the award of Master of Science (M.Sc.) degree in Microbiology in the Department of Biological Sciences, College of Sciences, College of Science and Technology, Covenant University, Ota, Ogun.

Mr. J. A. Philip
(Secretary, School of Postgraduate Studies)

.....
Signature and Date

Prof. S. Wara
Dean, School of Postgraduate Studies

.....
Signature and Date

Declaration

I hereby declare that this research work titled “**PRECLINICAL *IN VITRO* STUDY ON AMIDINE-HYDROXAMIC ACID BASED ANTIMALARIAL DRUG CANDIDATE**” was undertaken by **OPENIBO, JOHN OLUWAYOMI**. It is based on my original study in the Department of Biological Sciences, College of Science and Technology, Covenant University, Ota, under the supervision of Dr. G. I. Olasehinde and the ideas and the views of other researchers have been duly expressed and acknowledged.

Openibo, John Oluwayomi
(Student)

Signature and Date

Certification

This is to certify that the project titled: “**Preclinical *in vitro* study on amidine-hydroxamic acid based antimalarial drug candidate**” is a record of a project research work carried by out by Mr. **OPENIBO, JOHN OLUWAYOMI** (Matriculation Number: **14PCQ01212**) in the Department of Biological Sciences, School of Natural and Applied Sciences, College of Science and Technology, Covenant University, Ota, under the supervision of **Dr. G.I. Olasehinde**.

Dr. G.I. Olasehinde
(Supervisor)

Signature and Date

Prof. A. A. Ajayi
(Head of Department)

Signature and Date

Prof. A. Sanni
(External Examiner)

Signature and Date

Dedication

This dissertation is dedicated to God Almighty, the giver of wisdom, knowledge and understanding, as well as researchers who are contributing towards the elimination of Malaria disease.

Acknowledgements

My unreserved gratitude goes to Almighty God for his sustenance all through my course work and this research work. My appreciation also goes to The World Academy of Science (TWAS) in collaboration with Covenant University Bioinformatics Research Cluster (CUBRe) for providing the platform for me to undertake this Master degree programme in Microbiology.

I appreciate the effort of Dr G. I. Olasehinde (my supervisor) for her intellectual contributions and guidance in the course of this research work. I appreciate the effort of the faculty members in CUBRE: Prof. Adebisi E., Dr Ogunlana O.O., Dr Dokunmu T.M., Dr Rotimi S.O., Dr Adebayo A.H.; for their intellectual contributions and guidance.

To my TWAS/CUBRe colleagues (Onile-ere Olabode; Ofor Gloria and Awogbindin Victoria), thanks for your support throughout the thick and thin periods of this research work as well as your intellectual contributions.

I recognise and appreciate the contribution of persons such as Oluseye Oreoluwa, Igwe Tochukwu Titilayo, Ordor Oluchi Nelly and Opadiran Deborah; who donated blood that was used at one time or the other during the course of this project research.

My profound gratitude goes to Mr and Mrs Openibo for being there always for me. Thanks for your love and support that has seen me thus far in life. To my dearest sister, Adebajo Bernadette Adepeju, I deeply appreciate your love and support.

To the members of Faculty and Staff of the Department of Biological Sciences, Covenant University, I am grateful for the assistance and support you provided towards my success on this degree programme.

To all my well-wishers who supported me spiritually and financially in the course of this degree programme, May God reward you bountifully.

Openibo John O.

Table of content

Acceptance	ii
Declaration.....	iii
Certification.....	iv
Dedication	v
Acknowledgements	vi
Table of contents	vii
List of tables.....	ix
List of figures.....	x
List of plates.....	xi
Abstract.....	xii
CHAPTER ONE	13
INTRODUCTION.....	13
1.1. Statement of research problem.....	14
1.2. Justification of research	15
1.3. Aim and objectives of research	15
CHAPTER TWO	17
LITERATURE REVIEW	17
2.1 MALARIA	17
2.1.1. Aetiological agent	18
2.1.2. Life cycle	19
2.1.3. Epidemiology of malaria.....	20
2.1.4. Clinical signs and symptoms of malaria	21
2.1.5. Malaria burden	22
2.1.6 Control	22
2.1.7. Challenges.....	23
2.2 ANTIMALARIAL DRUGS	23
2.2.1. Categories and their actions	23
2.2.2. ANTIMALARIAL DRUG RESISTANCE (ARTEMISININ).....	26
2.3 DRUG DISCOVERY	28
2.3.2. Structure-based computer-aided drug design.....	30
2.3.3. Ligand-based computer-aided drug design	32
2.4 AMIDINE-HYDROXAMIC ACID BASED ANTIMALARIAL DRUG.....	32
2.4.1 Background and synthesis.....	32
2.4.2 Antimalarial activities	34
2.5 PRE-CLINICAL IN VITRO STUDY	34
CHAPTER THREE	39

MATERIALS AND METHODS	39
3.1 In vitro chemosensitivity of wild type Plasmodium falciparum	39
3.2. In vitro culture and chemosensitivity Plasmodium falciparum 3D7 strain.....	40
3.2.8. Data analysis	43
CHAPTER FOUR.....	44
RESULT AND DISCUSSION	44
4.1. Wild type and typed Plasmodium falciparum strain in vitro study.....	44
CHAPTER FIVE	59
CONCLUSION AND RECOMMENDATIONS.....	59
CONCLUSION	59
RECOMMENDATIONS.....	59
CONTRIBUTIONS TO KNOWLEDGE.....	59
REFERENCES.....	60
APPENDIX 1.....	66
MATERIALS	66
Consumables	66
Chemicals and drugs	66
Apparatus	66
Equipments	66
APPENDIX 2.....	67
MICROSCOPY IMAGES.....	67
APPENDIX 3.....	68
DRUG AND REAGENTS PREPARATION.....	68
Drug preparation for typed strains antimalarial efficacy	68
Drug preparation for wild type antimalarial efficacy	69
APPENDIX 4.....	72
WILD TYPE DATA OUTPUT.....	72
Wild type data output (regression)	73
Type strain data output (regression).....	76
APPENDIX 5.....	79
QUALITY CONTROL.....	79
Media Preparation.....	79
APPENDIX 6.....	85
INFORMED CONSENT FORM.....	85

List of tables

Table 2.1: Position of resistance in antimalarials drugs.	27
Table 2.2: RPMI 1640 tissue culture medium constituents.	36
Table 3.1: Study Population.....	45
Table 3.2: Number of positive blood samples by RDT and microscopy.	46
Table 3.3: Dose sensitivity of wild type <i>Plasmodium falciparum</i> strain (3D7) to OA2.	47
Table 3.4 : IC ₅₀ values of wild type <i>Plasmodium falciparum</i> strain.....	51
Table 3.5: Dose sensitivity of typed <i>Plasmodium falciparum</i> strain (3D7) to OA2.....	52
Table 3.6: IC ₅₀ values of typed <i>Plasmodium falciparum</i> strain (3D7).....	56
Table 3A: Molar concentration for OA2	68
Table 3B: Final well concentration for OA2	69
Table 3C: Final Well Concentrations	70
Table 4A: Arrangement on drugs in wells.....	72
Table 4B: Percentage (%) Parasitemia (no of schizonts/ RBC *100)	72
Table 4C: Regression output for Artemisinin.....	73
Table 4D: Regression output for Chloroquine.....	74
Table 4E: Regression output for OA2	75
Table 4F: Regression output for Artemisinin	76
Table 4G: Regression output for Chloroquine.....	77
Table 4H: Regression output for Artemisinin.....	78
Table 5A: Quality Control Results	80

List of figures

Figure 2.1: Geographical distribution of malaria prevalence globally	18
Figure 2.3: Structure of antimalarial drugs	25
Figure 2.5: Pathways of computer aided drug design.....	31
Figure 2.6: Synthesis of amidines from carboxylic acids and amines.....	33
Figure 2.7: Synthesis of cyclic amidine from diamines.....	33
Figure 2.8: Synthesis of cyclic Hydroxamic acid	33
Figure 3.1: Dose Response Plot for Artemisinin (Wild type strain).....	48
Figure 3.2: Dose Response Plot for Chloroquine (Wild type strain).....	49
Figure 3.4: Dose Response Plot for Artemisinin (Typed strain)	53
Figure 3.5: Dose Response Plot for Chloroquine (Typed strain).....	54

List of plates

Plate 2A: Schizont stage of <i>Plasmodium falciparum</i> in thick film X100.....	67
Plate 2A: White Blood Cells in thick film (Negative for malaria) X100.	67
Plate 5A&B: Micrograph showing gram stain smears from centrifuge (pre and post)	81
Plate 5E: Micrograph showing gram stain smears from contaminated culture	83

Abstract

The emergence of drug resistant strains of malaria parasite has led to increased efforts to discover and develop new antimalarial drugs that are structurally distinct from already existing ones. This study was conducted to evaluate the antiplasmodial activity of novel amidine-hydroxamic acid derivatives. Chloroquine-sensitive – Pyrimethamine resistant *Plasmodium falciparum* 3D7 strain was cultured *in vitro* in O⁺ human red blood cells in RPMI 1640 medium supplemented with 10% heat inactivated O human serum, 25mM HEPES buffer, 50µg/ml penicillin and 50µg/ml streptomycin under a condition of 90% N₂, 5% O₂ and 5% CO₂. Serially diluted drugs were seeded into 96-well microtitre plates and incubated with aliquots of parasite from 3D7 culture medium containing asynchronized stage of parasite at a parasitemia of 0.2% and an haematocrit of 4% and the asynchronized wild type *P. falciparum* blood sample at a parasitemia of 1% and 4% haematocrit. The results obtained from the inhibitory concentrations (IC₅₀) analyses performed for the novel antimalarial drug candidate compound revealed that the test compound with the code OA2 has IC₅₀ values of 15,960nM against *Plasmodium falciparum* 3D7 and 0.3941nM against the wild type *Plasmodium falciparum*, while the standard drugs Artemisinin and Chloroquine were 68.86nM and 68.24nM and 164.5nM and 59.0nM for the wild type and typed strain *Plasmodium falciparum*. From the result obtained, it can be inferred that OA2 is moderately active against the viability of *P. falciparum* in human blood cultures and hence may be promising antimalarial drug candidates.

KEYWORDS: Pre-clinical, *In vitro*, *Plasmodium* resistance, Novel Drug, Antimalarial.